Recombinant activated factor VII (rFVIIa, NovoSeven®)

M. B. Agarwal, M. Patnaik

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Recombinant activated factor VII (rFVIIa, NovoSeven®) enhances haemostasis in individuals, with its predominant action limited to areas of injury, apparently without systemic activation of the coagulation cascade. rFVIIa is currently licensed in most countries worldwide, for its use in the treatment of bleeding episodes in patients with hemophilia and the presence of inhibitors. Recently in the European Union, rFVIIa, has been approved for use in congenital Factor VII deficiency and Glanzmann's thrombasthenia. Furthermore, a large number of case series studies and anecdotal evidences, from patients with different bleeding conditions, have now shown that rFVIIa is actually a very valuable general haemostatic agent. It has been reported to reduce bleeding in patients with liver disease, thrombocytopenia/thrombocytopathia, trauma, spontaneous intracerebral hemorrhage and in the reversal of anticoagulant overdosage or toxicity. A number of trials have been carried out, which have shown that it is a relatively safe and well tolerated drug with a few episodes of unwanted thrombosis.

Original languageEnglish (US)
Pages (from-to)717-720
Number of pages4
JournalJournal of Association of Physicians of India
Issue numberAUG
StatePublished - Aug 1 2005

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Recombinant activated factor VII (rFVIIa, NovoSeven®)'. Together they form a unique fingerprint.

Cite this